BioSpace News Archive

Pfizer (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2 mRNA-based vaccine candidate against SARS-CoV-2 to European Union (EU) Member States, with an option for the European Commission to request an additional 100 million doses

NanoViricides, Inc.today reported that it has engaged Calvert Labs, a contract research organization (“CRO”), for performing the Safety Pharmacology studies of its clinical drug candidate for the treatment of COVID-19.

PolyPid Ltd. (Nasdaq: PYPD) (the “Company”), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2020.

Webcast to feature Theodore J. Daly, MD, FAAD, FSPD, FASD, 33-year dermatology veteran with more than 20 years of experience using excimer lasers

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that its Chief Executive Officer, Jesse Shefferman, will present at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 1:45pm ET. A webcast of the presentation can be accessed by visiting the Events and Presentations sect

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Management will present a company overview at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020 at 8:40 a.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the

Initiated rolling submission of New Drug Application (“NDA”) with U.S. Food and Drug Administration (“FDA”) O n track to submit complete NDA in Q1 202 1

-- Received $98.4 million in aggregate gross proceeds in October from initial public offering -- -- Initiated Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the treatment of solid tumors -- -- A nnounced c linical trial collaboration with Merck to evaluate combination of ONCR-177 with KEYTRUDA ® (pembrolizumab) as part of ongoing Phase 1 clinical trial

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today reported positive data from its ongoing Phase 1/2 clinical program in patients with X-linked retinitis pigmentosa (XLRP)